Description

RVD-Hpα TFA is the N-terminally extended form of human hemopressin that acts as a selective CB1 receptor agonist. RVD-Hpα TFA increases intracellular Ca2+ levels in cells expressing CB1 receptors in vitro. RVD-Hpα TFA also high affinity CB2 positive allosteric modulator (Ki=50 nM).–80°C, 2 years; -20°C, 1 year (Powder, sealed storage, away from moisture)–Neuroscience-Neuromodulation–C67H106F3N19O19——1431329-51-9–1538.67–99.32–OC(C(F)(F)F)=O.N=C(N)NCCC[C@H](N)C(N[C@@H](C(C)C)C(N[C@@H](CC(O)=O)C(N1[C@@H](CCC1)C(N[C@@H](C(C)C)C(N[C@@H](CC(N)=O)C(N[C@H](C(N[C@@H](CCCCN)C(N[C@@H](CC(C)C)C(N[C@@H](CC(C)C)C(N[C@@H](CO)C(N[C@H](C(O)=O)CC2=CN=CN2)=O)=O)=O)=O)=O)CC3=CC=CC=C3)=O)=O)=O)=O)=O)=O—-10 mM in DMSO–Cannabinoid Receptor–CB1–GPCR/G Protein;Neuronal Signaling–Peptides